fy15 duchenne muscular dystrophy research program (dmdrp)
applications to the fiscal year 2015 (fy15) duchenne muscular dystrophy research program (dmdrp) are being solicited for the defense health agency, research, development, and acquisition (dha rda) directorate, by the u.s. army medical research acquisition activity (usamraa). as directed by the office of the assistant secretary of defense for health affairs, the dha rda directorate manages and executes the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the executing agent for this program announcement/funding opportunity is the congressionally directed medical research programs (cdmrp). the dmdrp was initiated in 2011 to provide support for research of exceptional scientific merit and to promote the understanding, diagnosis, and treatment of dmd. appropriations for the dmdrp from fy11 through fy14 totaled $13.6 million (m). the fy15 appropriation is $3.2m.
the vision of the fy15 dmdrp is to extend and improve the function, quality of life, and lifespan for all individuals diagnosed with dmd. as such, the dmdrp is seeking to better support the development of drugs, devices, and other interventions and promote their effective clinical testing. additionally, dmdrp supports the efforts of the national institutes of health muscular dystrophy coordinating committee (mdcc) to update the action plan for the muscular dystrophies, which prioritizes the needs to improve treatments and reduce the disease burden for muscular dystrophy including duchenne.
funding awards available under this program
pre-application deadline: july 22, 2015; full application deadline: october 21, 2015.